Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

GLP-1 medications show mixed effects on body contouring outcomes

For patients undergoing body contouring surgery to remove excess abdominal skin after massive weight loss, use of GLP-1 weight-loss medications may have mixed effects on complication risks, suggests a study in the April issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.

26 Mar 2026

Mentally active sitting linked to reduced risk of dementia

New research distinguishing between passive and mentally active sitting in association with dementia has found that adults who engaged in extended durations of mentally passive sedentary behaviors had a higher risk of dementia.

26 Mar 2026

Can camel milk improve health? Review highlights benefits but warns against drinking it raw

A narrative review in Food Science & Nutrition examined studies published from 2000 to 2025 and found that camel milk contains bioactive compounds with potential glycemic, anti-inflammatory, gut, and other health benefits. It also stressed that raw, unpasteurized camel milk poses microbial and zoonotic risks, underscoring that safety remains a key part of the story.

25 Mar 2026

Eating more dairy and calcium may lower metabolic syndrome odds

Research links higher dietary calcium and dairy consumption to reduced odds of metabolic syndrome, highlighting potential dietary interventions for health.

25 Mar 2026

Algorithm-guided insulin dosing improves blood sugar control in type 2 diabetes

A University of Virginia Center for Diabetes Technology-developed algorithm – paired with a continuous glucose monitor – can help users better manage their type 2 diabetes by recommending insulin-dose adjustments, a new study found.

24 Mar 2026

Breast reduction surgery is linked to lower diabetes and heart risk

Findings suggest breast reduction surgery is associated with lower long-term diabetes and cardiovascular risks, enhancing women's metabolic health.

24 Mar 2026

Palmatine improved fatty liver markers in a preclinical type 2 diabetes study

Researchers used a bioinformatics-plus-rat-model approach to investigate how palmatine may help treat T2DM-associated MASLD, identifying five core targets: ADRB2, BCL3, EGR1, FOS, and MAP3K8. In rats, palmatine improved liver injury, inflammation, oxidative stress, glycolipid metabolism, steatosis, and fibrosis, while reducing apoptosis-related signaling, providing a preclinical foundation for further therapeutic study.

23 Mar 2026

Early obesity treatment reduces long-term health risks for all children

Children living with obesity but showing no signs of metabolic complications still have a significantly increased risk of developing type 2 diabetes, high blood pressure, and abnormal blood lipid levels later in life.

23 Mar 2026

Firmer potatoes lower post-meal blood sugar spikes

Minimally cooked potatoes may reduce blood sugar spikes, but benefits are short-lived and specific to certain populations, as shown in recent research.

23 Mar 2026

Replacing sedentary time improves insulin resistance in adolescents

Adolescents who replaced just half an hour of sedentary behaviors, such as sitting on the couch or spending time at the computer, each day for moderate-to-vigorous physical activity or sleep may lower their insulin resistance, a key factor in preventing the development of Type 2 diabetes, according to preliminary research presented at the American Heart Association's EPI|Lifestyle Scientific Sessions 2026.

23 Mar 2026

Oral semaglutide fails to slow early Alzheimer’s decline in two phase 3 trials

Two large phase 3 trials found that oral semaglutide 14 mg did not slow cognitive or functional decline over 104 weeks in people with early symptomatic, amyloid-positive Alzheimer’s disease. Semaglutide was generally consistent with its known safety profile and showed some biomarker changes, but these did not translate into clinical benefit.

22 Mar 2026

GLP-1 drugs cut heart and kidney risks in type 1 diabetes study

In a large target trial emulation of 174,678 people with type 1 diabetes, GLP-1 receptor agonist initiation was associated with lower risks of major cardiovascular events and end-stage kidney disease over five years. The study also found no increased risk of hospitalization for diabetic ketoacidosis or severe hypoglycemia, supporting further randomized trials of GLP-1RAs as adjunctive therapy in type 1 diabetes.

22 Mar 2026

AI diet plans underestimate teen nutrition and miss key nutrients

AI tools for adolescent diet planning may fall short, consistently underestimating nutrient intake and energy needs compared to individualized dietitian plans.

20 Mar 2026

Mandated caps reduce insulin out-of-pocket costs among US Medicare beneficiaries

A new analysis led by researchers at the Johns Hopkins Bloomberg School of Public Health finds that out-of-pockets caps on insulin for Medicare Part D beneficiaries have reined in insulin prices.

19 Mar 2026

How long should you take GLP-1 drugs? Study links longer use to lower heart risk

Continuous use of GLP-1 receptor agonists in adults with type 2 diabetes was associated with a lower risk of major cardiovascular events compared with sulfonylureas, with benefits increasing over time. Discontinuation or interruption was associated with a progressive loss of this protective effect, with risks approaching those of comparator therapy.

19 Mar 2026

Early morning workouts may improve cardiometabolic health

People who regularly exercised early in the morning were significantly less likely to have coronary artery disease, high blood pressure, Type 2 diabetes or obesity compared with people who exercised later in the day, according to a study being presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

19 Mar 2026

People with type 1 diabetes face higher risk of developing dementia

Having type 1 diabetes is associated with a higher risk of developing dementia, according to a study published March 18, 2026, in Neurology®, the medical journal of the American Academy of Neurology.

18 Mar 2026

Stopping GLP-1 treatment linked to increase in risk of major cardiovascular events

Following a rapid increase in popularity of GLP-1 drugs for diabetes and weight loss, such as semaglutide and tirzepatide, approximately one in eight U.S. adults now take these medications, which also provide cardiovascular benefits.

18 Mar 2026

Study finds GLP-1 medicines cut fat while preserving muscle function

Researchers found that GLP-1 medicines caused weight loss mainly through fat reduction, with only modest decreases in absolute muscle mass and no disproportionate loss of muscle function. In mice, physical performance improved, while in a small 12-week human pilot trial, strength was preserved despite reduced thigh muscle size.

18 Mar 2026

More US adolescents are obese but fewer are trying to lose weight

The rising obesity rates in American adolescents, coupled with declining weight-loss efforts, signal urgent needs for targeted public health interventions.

18 Mar 2026